Inclisiran is a double-stranded small RNA molecule that works by blocking the transcription of proprotein convertase subtilisin kexin 9 (PCSK-9), leading to a reduction of PCSK-9 levels in the hepatocytes, resulting in an increased expression of low-density lipoprotein (LDL) receptors in the hepatocyte membrane and, as a consequence, it reduces the circulating levels of LDL cholesterol (LDL-C).